Literature DB >> 22538218

Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization.

U Introini1, G Casalino, G Querques, A T Gimeno, F Scotti, F Bandello.   

Abstract

PURPOSE: To evaluate changes in macular morphology due to myopic choroidal neovascularization (CNV), using spectral-domain optical coherence tomography (SD-OCT).
METHODS: In all, 22 eyes with recent-onset untreated CNV underwent 1 intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF), followed by a pro-re-nata regimen. SD-OCT was performed at baseline (before first administration of anti-VEGF treatment) and month 1, and 2; macular morphologic changes and outer retina characteristics (SD-OCT findings) associated with CNV activity were evaluated. Sensitivity and specificity were calculated for SD-OCT findings using fluorescein angiography (FA) as standard reference.
RESULTS: Mean central retinal thickness (CRT) showed no significant reduction from baseline (284±98 μm) to month 1 (257±74 μm) and month 2 (263±72 μm). A hyper-reflective lesion with fuzzy borders (fuzzy area), and 'absent or altered' IS/OS junction were the only SD-OCT findings associated with CNV activity (P<0.0001). Both these SD-OCT findings showed good sensitivity and specificity (95.1 and 96.0% (95% CI: 0.87-0.89), respectively, for the fuzzy area; 87.9 and 66.7% (95% CI: 0.65-0.87), respectively, for 'absent or altered' IS/OS junction) when compared with FA leakage (standard reference).
CONCLUSIONS: Outer retina characteristics (ie, hyper-reflective lesion with fuzzy borders, and 'absent or altered' IS/OS junction) appear more meaningful than CRT in the evaluation of myopic CNV activity. These SD-OCT findings show overall good sensitivity and specificity when compared with FA leakage (standard reference), and could be considered as an alternative diagnostic tool to FA for myopic CNV monitoring.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538218      PMCID: PMC3396175          DOI: 10.1038/eye.2012.75

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  23 in total

1.  Photoreceptor layer features in eyes with closed macular holes: optical coherence tomography findings and correlation with visual outcomes.

Authors:  Natalia Villate; Ji Eun Lee; Anna Venkatraman; William E Smiddy
Journal:  Am J Ophthalmol       Date:  2005-02       Impact factor: 5.258

2.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

3.  The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Roberta Rigault de la Longrais; Giambattista Ravera; Chiara M Eandi; Luca Ventre; Ali' Abdollahi; Marilisa Manea
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.

Authors:  Frank G Holz; Winfried Amoaku; Juan Donate; Robyn H Guymer; Ulrich Kellner; Reinier O Schlingemann; Andreas Weichselberger; Giovanni Staurenghi
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

7.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

8.  Myopic choroidal neovascularization: a 10-year follow-up.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Kenjiro Yasuzumi; Ariko Kojima; Noriaki Shimada; Soh Futagami; Takashi Tokoro; Manabu Mochizuki
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

9.  Natural history of choroidal neovascularization in degenerative myopia.

Authors:  M P Avila; J J Weiter; A E Jalkh; C L Trempe; R C Pruett; C L Schepens
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

10.  Visual prognosis of disciform degeneration in myopia.

Authors:  G R Hampton; D Kohen; A C Bird
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

View more
  12 in total

Review 1.  Optical coherence tomography and pathological myopia: an update of the literature.

Authors:  Maria Vittoria Cicinelli; Luisa Pierro; Marco Gagliardi; Francesco Bandello
Journal:  Int Ophthalmol       Date:  2015-08-12       Impact factor: 2.031

Review 2.  Advances of optical coherence tomography in myopia and pathologic myopia.

Authors:  D S C Ng; C Y L Cheung; F O Luk; S Mohamed; M E Brelen; J C S Yam; C W Tsang; T Y Y Lai
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

3.  A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Authors:  Alfredo Pece; Paolo Milani; Carla Monteleone; Costantino John Trombetta; Giuseppe De Crecchio; Giuseppe Fasolino; Domenica Matranga; Salvatore Cillino; Maria Vadalà
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-13       Impact factor: 3.117

4.  The effect of center point shift on the measurement of macular thickness: a spectral domain-optical coherence tomography study.

Authors:  Kyoung Nam Kim; Il Hwan Shin; Jae Yun Sung; Baek Soo Kwak; Hyung Bin Lim; Young Joon Jo; Jung Yeul Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-06       Impact factor: 3.117

5.  Retinal pigmental epithelium elevation and external limiting membrane interruption in myopic choroidal neovascularization: correlation with activity.

Authors:  Xiaoyan Ding; Zongyi Zhan; Limei Sun; Yu Yang; Songshan Li; Aiyuan Zhang; Xiaoling Luo; Lin Lu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-07-07       Impact factor: 3.117

6.  Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy?

Authors:  Paolo Milani; Marco Pellegrini; Amedeo Massacesi; Stefania Moschini; Marco Setaccioli; Davide Soranna; Antonella Zambon; Ferdinando Bottoni; Fulvio Bergamini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-30       Impact factor: 3.117

7.  Long-term outcomes of myopic choroidal neovascularisation treated with combined ranibizumab and dexamethasone characterised by multi-modal imaging.

Authors:  Anna C S Tan; Kelvin Teo; Ong Sze Guan; Adrian Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-12       Impact factor: 3.117

8.  Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response.

Authors:  Niccolò Castellino; Maurizio Battaglia Parodi; Andrea Russo; Mario Damiano Toro; Matteo Fallico; Vincenza Bonfiglio; Agatino Davide Maugeri; Teresio Avitabile; Antonio Longo
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

9.  Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal Neovascularization due to Myopia.

Authors:  Maria-Magdalena Guichard; Géraldine Peters; Cengiz Tuerksever; Christian Pruente; Katja Hatz
Journal:  Ophthalmologica       Date:  2019-08-06       Impact factor: 3.250

10.  Assessment of Posterior Segment Using Spectral Domain OCT in Highly Myopic Eyes.

Authors:  Heba Radi AttaAllah; Ismail Ahmed Nagib Omar; Ahmed Shawkat Abdelhalim
Journal:  Open Ophthalmol J       Date:  2017-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.